Navigation Links
Jennerex Announces Presentations at Upcoming Conferences
Date:12/23/2009

SAN FRANCISCO, Dec. 23 /PRNewswire/ -- Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.


    Biotech Showcase 2010
    Tuesday, January 12, 2010
    9:40 a.m. PT
    Marines' Memorial Club and Hotel, San Francisco

    OneMedForum 2010
    Wednesday, January 13, 2010
    2:40 p.m. PT
    Sir Francis Drake Hotel, San Francisco

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .

SOURCE Jennerex Biotherapeutics


'/>"/>
SOURCE Jennerex Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
2. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
3. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
6. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
7. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
8. Macomb County Announces Final 2009 H1N1 Clinic
9. Access MediQuip Announces Release of Partners in Focus Provider Portal
10. Unilens Announces Extraordinary Meeting Results
11. Arrayit Corporation Announces Manufacturing Breakthrough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015  AbbVie (NYSE: ABBV ... Conference on Thursday, March 12, 2015. Richard A. ... in a question and answer session at 8:30 a.m. ... the presentation will be accessible through AbbVie,s Investor Relations ... of the session will be available later that day. ...
(Date:3/6/2015)... 6, 2015 Troyen A. Brennan, M.D., M.P.H., ... Health (NYSE: CVS ), will speak before ... Washington, D.C. today.  Brennan will outline ways ... health care cost and quality as the overall health ... first national pharmacy chain to stop selling tobacco in ...
(Date:3/6/2015)... March 6, 2015   Veracyte, Inc. (Nasdaq: ... that diagnostic tests that use increasing numbers of cancer-associated ... the specificity of test results, leading to an increase ... diagnosed as cancerous. In addition, these new data show ... malignancies leading to "false negatives." The data were presented ...
Breaking Medicine Technology:CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 2Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 4Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 5Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 6
... China, July 25, 2011 /PRNewswire-Asia/ -- The whole healthcare ... technology trends and social economic increases. Generally speaking, several ... rapid increase of world population especially the aging ... are increasing in both developed and developing countries. They ...
... Colo., July 25, 2011 Lanx®, Inc., a privately ... innovative devices for spinal surgery, announced its Aspen™ Spinous ... presentations at The 18th International Meeting on Advanced Spine ... Dan Gladney, Chief Executive Officer, Lanx, commented, ...
Cached Medicine Technology:Avoid Illness Through Easy Daily Check 2Lanx, Inc. Announces Aspen™ Spinous Process Fixation System Clinical Data at IMAST 2Lanx, Inc. Announces Aspen™ Spinous Process Fixation System Clinical Data at IMAST 3
(Date:3/6/2015)... 2015 Saving Moses, a global humanitarian ... is traveling to Angola, Africa March 7-14 to visit ... program. , This will be the organizations fifth time ... their commitment to the region’s population by saving infants ... engage with the mothers and babies of the malnutrition ...
(Date:3/6/2015)... 2015 Ticket Down is a reputable source ... at the Moda Center. After being away from the ... showing no signs of letting up on his “Garth Brooks ... his wife, Trisha Yearwood, to venues around the United States. ... critically acclaimed tour to the Moda Center in Portland, OR. ...
(Date:3/6/2015)... 06, 2015 Follow us on ... pharmacokinetics of a drug refers to testing of absorption, ... an organism. When toxicity studies are clubbed together with ... ADME/Tox. Increasing focus on lowering costs and time during ... worldwide. The traditional drug development model uses toxicity and ...
(Date:3/6/2015)... 2015 As the Muscular Dystrophy Association ... the organization has hired two new Scientific Program Officers, ... will report to Grace Pavlath, Ph.D, who joined MDA ... Program Director, and together will lead MDA as it ... cures for various types of neuromuscular and motor neuron ...
(Date:3/6/2015)... March 06, 2015 “On Tap” takes the ... the grand stage, to the silver screen and to modern ... precision toe-tapping numbers and their famous eye-high kicks! Producers, directors ... rich history of tap dancing in this robust show, showcasing ... of the United States. , “On Tap” is proud ...
Breaking Medicine News(10 mins):Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
... CEL-SCI Corporation,(Amex: CVM ) announced today that it ... its new website. The link is located in,the top ... http://www.cel-sci.com . Geert Kersten, Chief Executive Officer ... the future of cancer therapy. We have,created an easy ...
... Inc., the leading,provider of Web-based employee performance and ... Halogen eAppraisal with,Multi-Rater. Vonage, a leading provider of ... to streamline the appraisal process for HR,managers and ... its,customers. Vonage will be replacing its current ...
... world because of lack of investment in trained personnel, ... Duke of York, Patron of the Association of Anaesthetists ... foreword to a special supplement on anaesthesia in the ... says that this situation is in stark contrast to ...
... Disparities in access to health care and education ... needed cancer services and often lead to delayed ... cancer education geared toward African-Americans, researchers with the ... with The Centers for Healthy Hearts and Souls, ...
... is expected to meet growing demand for reconciling medications ... ... adoption of CPOE, SAN BRUNO, Calif., ... has licensed First DataBank,s,OrderView Med Knowledge Base(TM), a computerized physician ...
... REDWOOD CITY, Calif., Oct. 29 /PRNewswire-FirstCall/-- Cardica, Inc.,(Nasdaq: ... subject to market,and other conditions, 1,500,000 shares of its ... its common stock for sale by a selling,stockholder in ... from sales of shares made by the selling stockholder. ...
Cached Medicine News:Health News:Vonage Selects Halogen Software - New Solution to Streamline Employee Performance and Talent Management Across Organization 2Health News:British Royal highlights anesthesia crisis in the developing world 2Health News:Education program leads to lasting improvement of cancer knowledge in African-Americans 2Health News:HealthTek Software Solutions Licenses First DataBank's OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation 2Health News:HealthTek Software Solutions Licenses First DataBank's OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation 3Health News:HealthTek Software Solutions Licenses First DataBank's OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation 4Health News:Cardica Announces Proposed Public Offering of Common Stock 2Health News:Cardica Announces Proposed Public Offering of Common Stock 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: